

# A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands

**A Gupta<sup>1</sup>, MJ Roobol<sup>2</sup>, CJ Savage<sup>1</sup>, M Peltola<sup>3</sup>, K Pettersson<sup>2</sup>, PT Scardino<sup>1</sup>, AJ Vickers<sup>1</sup>, FH Schröder<sup>2</sup> and H Lilja<sup>\*,1,4</sup>**

<sup>1</sup>Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; <sup>2</sup>Erasmus Medical Centre, Department of Urology, room NH-224, P.O. Box 2040, 3000 CA, Rotterdam, Netherlands; <sup>3</sup>Department of Biotechnology, University of Turku, Tykistökatu 6 A 6th floor, FIN-20520 Turku, Finland; <sup>4</sup>Lund University, Malmö University Hospital, Malmö, Sweden

**BACKGROUND:** Most men with elevated levels of prostate-specific antigen (PSA) do not have prostate cancer, leading to a large number of unnecessary biopsies. A statistical model based on a panel of four kallikreins has been shown to predict the outcome of a first prostate biopsy. In this study, we apply the model to an independent data set of men with previous negative biopsy but persistently elevated PSA.

**METHODS:** The study cohort consisted of 925 men with a previous negative prostate biopsy and elevated PSA ( $\geq 3$  ng ml<sup>-1</sup>), with 110 prostate cancers detected (12%). A previously published statistical model was applied, with recalibration to reflect the lower positive biopsy rates on rebiopsy.

**RESULTS:** The full-kallikrein panel had higher discriminative accuracy than PSA and DRE alone, with area under the curve (AUC) improving from 0.58 (95% confidence interval (CI): 0.52, 0.64) to 0.68 (95% CI: 0.62, 0.74),  $P < 0.001$ , and high-grade cancer (Gleason  $\geq 7$ ) at biopsy with AUC improving from 0.76 (95% CI: 0.64, 0.89) to 0.87 (95% CI: 0.81, 0.94),  $P = 0.003$ . Application of the panel to 1000 men with persistently elevated PSA after initial negative biopsy, at a 15% risk threshold would reduce the number of biopsies by 712; would miss (or delay) the diagnosis of 53 cancers, of which only 3 would be Gleason 7 and the rest Gleason 6 or less.

**CONCLUSIONS:** Our data constitute an external validation of a previously published model. The four-kallikrein panel predicts the result of repeat prostate biopsy in men with elevated PSA while dramatically decreasing unnecessary biopsies.

*British Journal of Cancer* (2010) **103**, 708–714. doi:10.1038/sj.bjc.6605815 www.bjcancer.com

Published online 27 July 2010

© 2010 Cancer Research UK

**Keywords:** prostate cancer; biomarkers; predictive value of tests; prostate-specific antigen; cancer screening

Levels of prostate-specific antigen (PSA) in the blood are very strongly associated with clinically significant prostate cancer, whether in terms of high grade at diagnosis (Thompson *et al*, 2006) or subsequent clinical diagnosis of advanced cancer (Ulmert *et al*, 2008). However, the PSA test has only modest diagnostic specificity and positive predictive value for prostate cancer detection at commonly used cut-points. This leads to significant numbers of unnecessary biopsies. In the European Randomized Study of Prostate Cancer screening (ERSPC), for example, the positive biopsy rate among men with elevated PSA was 24.1% (Schroder *et al*, 2009a), suggesting that three out of every four biopsies were unnecessary. Similar findings have been reported from US studies, such as the Prostate Cancer Prevention Trial (PCPT) (Thompson *et al*, 2005). There is thus an urgent need to supplement PSA with novel biomarkers that enhance its specificity so that unnecessary biopsies can be avoided.

We have previously published a statistical model to predict the results of prostate biopsy. The model includes age, DRE and a panel of four kallikrein markers – total PSA, free PSA, intact PSA and human kallikrein-related peptidase-2 (hK2). Using data from the randomised prostate cancer screening trial in Göteborg, Sweden (one centre of the ERSPC), we estimated that for every 1000 previously unscreened men with elevated PSA, use of the model to determine biopsy would reduce biopsy rates by 573, while missing only a small number of cancers (31 out of 152 low-grade cancers and 3 out of 40 high-grade cancers) (Vickers *et al*, 2008). These findings were subsequently replicated in an independent cohort (reduction in biopsy by 513 per 1000 men with elevated PSA, missing 54 out of 177 low-grade cancer and 12 out of 100 high-grade cancers) (Vickers *et al*, 2010c). These findings have also been replicated in men who recently have undergone previous screening, with resultant improvements in predictive accuracy (Vickers *et al*, 2010a, b).

The performance characteristics of PSA are known to be influenced by previous screening, with predictive accuracy lower in men who have previously been screened compared with an unscreened cohort of men (Vickers *et al*, 2010a). Similarly, the predictive accuracy of PSA to predict the outcome of repeat biopsy

\*Correspondence: Dr H Lilja; E-mail: liljah@mskcc.org

Received 4 May 2010; revised 24 June 2010; accepted 29 June 2010; published online 27 July 2010

after initial negative biopsy is also lower (Roobol *et al*, 2006; Walz *et al*, 2006; Chun *et al*, 2007). In this study, we have evaluated the performance characteristics of PSA in men who underwent a second biopsy after an initial negative biopsy in the Rotterdam section of the ERSPC. We then evaluated the performance characteristics of the kallikrein panel in this cohort to see whether it also could provide a more accurate prediction of repeat biopsy outcome than currently established standard predictors. This also serves as an independent validation of our previously published model to predict the results of prostate biopsy.

## MATERIALS AND METHODS

### Patient methods

The study cohort comprised of participants in the Rotterdam section of the ERSPC. The study design has been described previously (Roobol *et al*, 2003). In brief, men aged 55–75 years were invited for an initial PSA test during 1993–1999; men not diagnosed with prostate cancer were invited for up to two subsequent screens every 4 years until they reached age 75 years. All biopsies were prompted by an elevated PSA ( $\geq 3$  ng ml<sup>-1</sup>). A total of 3394 patients had initial negative biopsy in rounds 1 through 3. Of these, 1000 men underwent a second biopsy in subsequent rounds and 2394 men did not undergo a second biopsy for various reasons (Figure 1). Biomarkers data were not available for 75 of the 1000 men who underwent a second biopsy. Our analysis is focused on the 925 men who underwent a second prostate biopsy after an initial negative biopsy using an aliquot of the blood collected before the second biopsy.

### Laboratory methods

Laboratory methods were as for our previous publication (Vickers *et al*, 2008). Serum samples were retrieved from the archival serum bank in Rotterdam (where they had been stored frozen at  $-80^{\circ}\text{C}$  after their initial processing within 3 h from venipuncture) and shipped frozen on dry ice to Malmö, Sweden, in 2005–2007. Analyses of free, total, and intact PSA and hK2 were performed in

Dr Lilja's laboratory at the Wallenberg Research Laboratories, Department of Laboratory Medicine, Lund University, University Hospital UMAS in Malmö, Sweden, during 2005 and 2007. Free and total PSA were measured using the dual-label DELFIA Prostatus total/free PSA-Assay (Perkin-Elmer, Turku, Finland) and conducted in accordance with WHO calibration standards. The measurements of intact PSA and hK2 entailed the use of F(ab')<sub>2</sub> fragments of the monoclonal capture antibodies in order to significantly reduce the frequency of nonspecific assay interference (Vaisanen *et al*, 2006). The intact PSA assay measures only free, uncomplexed intact PSA (i.e., not cleaved at Lys<sub>145</sub>–Lys<sub>146</sub>). All analyses were conducted blind to biopsy result.

### Statistical methods

Our aim was to compare the area under the curve (AUC) of our previously developed statistical model, which included age, DRE result and a panel of four kallikrein markers *vs* that of a base model that included age, DRE result and total PSA. To determine the predictive value of our previously developed statistical model (age, DRE and four kallikreins) above that of age, DRE and total PSA alone, we looked at the area under the receiver operating characteristic curve (AUC). High-grade cancer was defined as biopsy Gleason score 7 or higher. Separate models were not built for high-grade cancer, and the AUC for high-grade cancer was calculated from the predicted probabilities of any cancer. The predicted risk from the model was recalibrated with a Bayes factor, using the observed event rate in this cohort (12%) to reflect the lower incidence of cancer in men with previous negative biopsy. Previous studies have reported higher rates of prostate cancer on repeat biopsy, ranging from 11 to 34% (Keetch *et al*, 1994; Roehrborn *et al*, 1996; Catalona *et al*, 1997; Fleshner *et al*, 1999; Letran *et al*, 1998; Rietbergen *et al*, 1998; Durkan and Greene, 1999; Djavan *et al*, 2000; O'Dowd *et al*, 2000; Stewart *et al*, 2001; Lopez-Corona *et al*, 2003; Park *et al*, 2003; Lujan *et al*, 2004; Walz *et al*, 2006; Benecchi *et al*, 2008; Lane *et al*, 2008; Rochester *et al*, 2009; Schroder *et al*, 2009b). Therefore, to examine the impact this adjustment would have on calibration (discrimination would not be affected) in cohorts with a different rate of cancer detection




Figure 1 Flow chart of participants in the study.

on repeat biopsy, we simulated higher event rates by randomly sampling with replacement to create data sets with observed event rates of 20 or 30%.

To illustrate the clinical effects of using the four-kallikrein model in men with repeat biopsy, we used decision curve analysis. Decision curve analysis estimates a 'net benefit' for prediction models by summing the benefits (true positives) and subtracting the harms (false positives), where the latter is weighted by a factor so as to reflect the relative harm of a missed cancer compared with an unnecessary biopsy. The weighting is derived from the threshold probability of prostate cancer, defined as the point at which a patient would choose to be biopsied. As this threshold probability can vary from patient to patient, net benefit is calculated across a range of probabilities; we chose 10–40% as a reasonable range. The interpretation of a decision curve is straightforward: the model with the highest net benefit at a particular threshold probability should be used. All statistical analyses were conducted using Stata 10.1 (StataCorp LP, College Station, TX, USA).

## RESULTS

Characteristics of the participants who were biopsied after a previous negative biopsy are given in Table 1. In total, 110 (12%) of 925 men had a positive biopsy after a previous negative biopsy. The total PSA levels and age were only slightly higher for the men with positive second biopsies compared with those with negative biopsies (median total PSA: 5.61 vs 5.22 ng ml<sup>-1</sup> and age: 65 vs 64 years). As is typical for recently screened men, the majority of cancers diagnosed were Gleason 6 or less ( $n = 92$ ; 84%), whereas 13 (12%) were Gleason 7 and only 5 (5%) were Gleason 8 or higher.

The AUC of our previously developed model and base model when applied to men with a previous negative biopsy are given in Table 2. The AUC of the four-kallikrein panel was significantly higher than the base model for the prediction of any prostate cancer (AUC 0.681 (95% confidence interval (CI): 0.623, 0.739) vs 0.584 (95% CI: 0.523, 0.644),  $P < 0.001$ ) and high-grade cancer at biopsy (AUC 0.873 (95% CI: 0.807, 0.939) vs 0.764 (95% CI: 0.639, 0.888),  $P = 0.003$ ).

To put these results in a clinical context, we considered the scenario where a clinician would recommend biopsy to men with a predicted probability of 20% (Table 3). Applying this rule with the kallikrein model would reduce the number of biopsies by 82%, while delaying the diagnosis of 64 low-grade (Gleason sum  $\leq 6$  at biopsy) and 3 high-grade cancers per 1000 men with persistently elevated total PSA ( $\geq 3$  ng ml<sup>-1</sup>). In other words, for every 272 men who avoid biopsy, we miss only one high-grade cancer. In addition, all the three high-grade cancers that were missed were Gleason 7 and none of the cancers with Gleason score  $\geq 8$  were missed. The very large reduction in biopsies conducted and cancers found is due to the low event rate in this cohort. It seems reasonable to assume that men with a previous biopsy might be more risk averse than the population as a whole. Hence, we repeated this analysis using a 15 and 10% risks as thresholds for biopsy. Even at these lower risk thresholds, use of the model would avoid 71 and 54% of the biopsies, whereas missing only 3 and 1 high-grade cancers, all of which were Gleason 7 (Table 3).

Figure 2 shows the decision curve for our full kallikrein model. The net benefit of the four-kallikrein panel is superior to the alternative strategies of either biopsying all men, no men or biopsying on the basis of age, total PSA and DRE alone for all men, except those requiring a very high (>30%) risk of cancer before accepting biopsy. Such men should not be biopsied after negative biopsy, as their risk of subsequent positive biopsy is low.

As the event rate in this data set is lower than that previously reported in men undergoing a repeat biopsy, we conducted a sensitivity analysis to determine the effect of applying our

**Table 1** Participant characteristics

	No cancer (N = 815)	Cancer (N = 110)
Age at biopsy (years)	64 (61, 67)	65 (61, 68)
Total PSA (ng ml <sup>-1</sup> )	5.22 (4.07, 7.26)	5.61 (4.27, 8.93)
Free PSA (ng ml <sup>-1</sup> )	1.27 (0.93, 1.77)	1.22 (0.99, 1.61)
Intact PSA (ng ml <sup>-1</sup> )	0.67 (0.50, 0.96)	0.77 (0.52, 0.99)
Nicked PSA (ng ml <sup>-1</sup> )	0.58 (0.39, 0.87)	0.47 (0.31, 0.74)
hK2 (ng ml <sup>-1</sup> )	0.083 (0.058, 0.125)	0.101 (0.065, 0.141)
Abnormal DRE	173 (21%)	37 (34%)
<i>Biopsy Gleason score</i>		
≤6	—	92 (84%)
=7	—	13 (12%)
≥8	—	5 (5%)
Prostate volume at first biopsy <sup>a</sup>	48.6 (39.5, 60.7)	43.8 (33.5, 53.2)

Abbreviations: DRE = digital rectal examination; hK2 = human kallikrein-related peptidase-2; PSA = prostate-specific antigen. All values are median (interquartile range) or frequency (proportion). <sup>a</sup>Missing for four patients.

**Table 2** Area under the curve of models built on first round Rotterdam participants when applied participants in subsequent rounds with a previous negative biopsy and elevated PSA (3 ng ml<sup>-1</sup> or higher)

	Biopsy outcome of any prostate cancer	Biopsy outcome of high-grade prostate cancer
<i>Main analysis</i>		
Base model (age, total PSA and DRE)	0.584 (0.523, 0.644)	0.764 (0.639, 0.888)
Full model (age, kallikrein panel, DRE)	0.681 (0.623, 0.739)	0.873 (0.807, 0.939)
<i>P</i> -value for difference between base and full models	<0.001	0.003
<i>Sensitivity analysis: including prostate volume at first biopsy</i>		
Base model (age, total PSA, volume and DRE)	0.625 (0.567, 0.684)	0.839 (0.744, 0.933)
Full model (age, kallikrein panel, volume, DRE)	0.677 (0.619, 0.736)	0.867 (0.800, 0.935)
<i>P</i> -value for difference between base and full models	0.021	0.2

Abbreviations: DRE = digital rectal examination; hK2 = human kallikrein-related peptidase-2; PSA = prostate-specific antigen. High-grade cancer is defined as Gleason score  $\geq 7$ . Full model includes age, total PSA (with splines), free PSA (with splines), intact PSA, hK2 and DRE result.


recalibrated model to a cohort of men, in which the true event rate was higher (20 or 30%) than the event rate used for recalibration (12%). When the true event rate was 20%, the kallikrein model was superior to alternative treatment strategies for all threshold probabilities above 12% (Figure 3A). However, at an event rate of 30%, the kallikrein model was superior to a strategy of biopsying all men only at threshold probabilities above 26% (Figure 3B). This may be because the model was calibrated to a lower event rate of 12% and would likely need to be recalibrated for use in cohorts, in which positive rebiopsy rates are 30% or higher.

Several investigators have included prostate volume in predictive models for prostate cancer, for example, by calculating 'PSA density' (Radwan *et al*, 2007; Kranse *et al*, 2008). We have previously avoided this approach on the grounds that data on volume are only available when a transrectal ultrasound (TRUS) probe is inserted during a prostate biopsy session. In the case of repeat biopsy, however, TRUS-based prostate gland volume is

**Table 3** Clinical outcome of basing repeat biopsy on the kallikrein model

	No. of biopsies		No. of cancers		No. of high-grade cancers	
	Performed	Avoided (%)	Found	Not found (%)	Found	Not found (%)
Biopsy all (i.e., PSA > 3)	1000	0 (0)	119	0 (0)	19	0 (0)
Biopsy if risk ≥ 20% from the kallikrein model	183	817 (82)	52	67 (56)	16	3 (16) <sup>a</sup>
Biopsy if risk ≥ 15% from the kallikrein model	288	712 (71)	66	53 (45)	16	3 (16) <sup>a</sup>
Biopsy if risk ≥ 10% from the kallikrein model	459	541 (54)	82	37 (31)	18	1 (5) <sup>a</sup>

Abbreviation: PSA = prostate-specific antigen. Numbers are given per 1000 men with elevated PSA ( $\geq 3 \text{ ng ml}^{-1}$ ). <sup>a</sup>All the high-grade cancers that were missed were Gleason 7. None of the cancers with Gleason score  $\geq 8$  were missed.




**Figure 2** Decision curve for outcome of any cancer using the four-kallikrein model (dashed line) and base model (solid line), after recalibration. The solid grey line is for the strategy of biopsying all men and the horizontal black line for not biopsying anyone. The line with the highest net benefit at a particular threshold probability will lead to the best clinical results.

already available from the original negative biopsy session. As a sensitivity analysis, we added prostate volume to the base and full models that were built on the first round of Rotterdam participants and independently evaluated on men with a previous negative biopsy. As shown in Table 2, TRUS-based prostate gland volume increased the AUC of the base model, but not the full kallikrein model, and AUC remained higher for the full model than for base model (total PSA, age, and DRE) plus TRUS volume. The decision curve was not substantively affected (data not shown). Our conclusion that the kallikrein panel adds information to established predictors is therefore unchanged.

**DISCUSSION**

In this study, we found that a panel of four kallikreins can predict the outcome of prostate biopsy in men who had previously undergone prostate biopsy during previous screening. The full model comprised of the four kallikrein markers (i.e., total, free and intact PSA, and hK2), age and DRE substantially improved the predictive accuracy of a base model (comprising of total PSA, age and DRE), for both low- and high-grade cancers.

We have previously reported similar improvements in AUC by using the four-kallikrein panel in previously unscreened men and in men who had undergone previous screening but had not been biopsied; and have validated these findings in independent cohorts (Vickers *et al*, 2008, 2010a,b,c). Among men who have not been previously screened, use of the four-kallikrein panel increased the AUC for detecting prostate cancer from 0.685 to 0.776 (Vickers



**Figure 3** Decision curves for outcome of any cancer using the four-kallikrein model (dashed line), compared with a strategy of biopsying all men (solid grey line) or biopsying no men (solid black line) in cohorts in which the event rate was imputed to be 20% (A) or 30% (B).

*et al*, 2010c). For men who have previously been screened but not biopsied, the model increased AUC from 0.585 to 0.711 (Vickers *et al*, 2010b).

These results also support our previous finding that the predictive accuracy of PSA decreases in men who have previously been screened. The AUC of a base model comprising of total PSA, age and DRE was 0.584 to predict any cancer in this cohort as compared with 0.724 for a cohort of men who had never been screened (Vickers *et al*, 2008). The AUC of 0.584 in this study is similar to the AUC of 0.569 and 0.585 in two cohorts of men who had recently been screened in the ERSPC trial and undergone initial prostate biopsy due to elevated PSA, but had no previous biopsy (Vickers *et al*, 2010a,b). Similarly, for men with previous negative biopsies, two large studies using clinical cohorts of men

have found the AUC of total PSA alone to be modest at 0.528 and 0.601, respectively (Walz *et al*, 2006; Chun *et al*, 2007).

Men with prostate cancer after previous negative biopsy tend to have favourable disease and their outcomes are better than those diagnosed at the first screen (Schroder *et al*, 2009b). Most of these cancers are low risk and are likely to constitute overdiagnosis. Schroder *et al* (2009b) studied 3056 men in the Rotterdam arm of the ERSPC who had initial negative biopsies at the first screen. On follow-up up to 11 years, 287 prostate cancer cases were detected, 26 developed progressive disease and 7 died of prostate cancer (Schroder *et al*, 2009b). Of these seven deaths only one was diagnosed on repeat screening and the other six were interval cancers. Only 0.6% of the prostate cancers diagnosed on repeat screening after initial negative biopsy led to death, as compared with 4.2% death rate for cancers found at initial biopsy. Thus, very few cancers found after initial negative biopsy are clinically relevant. Biopsying all men with previous negative biopsies will lead to a large number of unnecessary biopsies and detection of a large number of potentially clinically insignificant cancers. Hence, a strategy of identifying and biopsying men at the greatest risk of death due to cancer is needed.

In this cohort, of the 110 cancers that were diagnosed, 84% had Gleason sum 6 or less on biopsy and only 5% were Gleason 8 or more. Similarly in a series of 99 men enrolled in a large screening programme with previous negative biopsies, 20 cancers were found. Of these only one was clinically advanced, only 1 had biopsy Gleason score 7 and three had Gleason score 7 on radical prostatectomy. No patient had Gleason 8 or higher (Catalona *et al*, 1997). Hence, due to the relatively large number of clinically insignificant cancers that exist in men with previous negative biopsies, the goal in these men is to reduce the number of biopsies, reduce the detection of clinically insignificant or indolent disease, while still detecting the clinically significant cancers.

Use of the four-kallikrein model to predict the result of repeat biopsy would lead to a very large reduction in the rate of unnecessary second biopsy. Of the men with cancer who would be classified at low risk from a model, the majority would have the sort of low-stage, low-grade cancers typically thought to constitute overdiagnosis. For example, if biopsy was based on patients having a risk of cancer of 20% or more, use of the model would reduce the number of biopsies by 82%. Of the 67 cancers that would be missed, 64 would be Gleason 6 or less. The diagnosis will be delayed for only 16% (3 of 19) of the high-grade cancers (Gleason score = 7). For men who are more risk averse and would prefer to undergo a biopsy at a 15% risk threshold, use of the model would still reduce the biopsies by 712 per 1000 men, while missing 53 cancers only 3 of which would be Gleason 7. Thus, use of such models may decrease the overdiagnosis and overtreatment associated with repeated screening and repeat biopsy in men with previous negative biopsies.

For men with previous negative biopsies and elevated PSA, use of other markers such as PCA3 has been suggested. In men with previous negative biopsies and persistently elevated PSA, a higher PCA3 score has been found to be associated with a higher probability of a positive biopsy (Marks *et al*, 2007; Haese *et al*, 2008). In a study of 463 men, use of a PCA3 score threshold of 20 would reduce 44% of the biopsies, while missing 9% of high-grade cancers (Haese *et al*, 2008). A higher threshold, such as 35, would avoid more biopsies (67%), but would also miss more high-grade cancers (21%). Direct comparison of these results with ours is not possible because ours is a screening cohort, whereas the PCA3 studies were based on clinical cohorts. The PCA3 test while promising needs to be validated in independent cohorts, and the PCA3 score needs to be incorporated into a model with other predictors of a positive biopsy such as age, DRE, PSA and other kallikreins. The need for an attentive DRE and collection of a urine sample for PCA3 measurement may also limit its utility in a screening scenario.

Several nomograms have also been developed to predict outcomes of biopsy in men after previous negative biopsies (Shariat *et al*, 2008). However, only a few of these have been externally validated (Lopez-Corona *et al*, 2003; Yanke *et al*, 2005; Chun *et al*, 2007). These nomograms have incorporated variables such as family history, PSA, free PSA, PSA kinetics, PSA density, biopsy findings, number of previous negative cores and so on. These nomograms were developed in clinical cohorts and need to be studied in screening cohorts before they can be used in a screening scenario.

Our study may be limited by the use of sextant biopsy, which misses 19–23% of the cancers compared with the currently practiced extended biopsy schemes (Schroder *et al*, 2009b). This may partially explain why the cancer detection rate on rebiopsy was 12% in this cohort compared with 11–19% reported in other screening cohorts and 16–34% reported in clinical cohorts (Keetch *et al*, 1994; Roehrborn *et al*, 1996; Catalona *et al*, 1997; Fleshner *et al*, 1997; Letran *et al*, 1998; Rietbergen *et al*, 1998; Durkan and Greene, 1999; Djavan *et al*, 2000; O'Dowd *et al*, 2000; Stewart *et al*, 2001; Lopez-Corona *et al*, 2003; Park *et al*, 2003; Lujan *et al*, 2004; Benecchi *et al*, 2008; Lane *et al*, 2008; Rochester *et al*, 2009; Schroder *et al*, 2009b). We attempted to evaluate our model in cohorts with higher cancer rates by varying the event rate using statistical imputation. We found that the model performed well when the event rate was as high as 20%, but without recalibration would not be clinically useful in cohorts with 30% or higher detection rates. However, most repeat biopsy studies in screening and clinical cohorts have found the cancer rate to be less than 30% (Keetch *et al*, 1994; Roehrborn *et al*, 1996; Catalona *et al*, 1997; Rietbergen *et al*, 1998; Djavan *et al*, 2000; O'Dowd *et al*, 2000; Lopez-Corona *et al*, 2003; Park *et al*, 2003; Lujan *et al*, 2004; Lane *et al*, 2008). The few studies that have found higher rates tended to be older series (Fleshner *et al*, 1997; Letran *et al*, 1998; Durkan and Greene, 1999); or involved saturation biopsies, usually after previous sextant biopsies (Stewart *et al*, 2001; Walz *et al*, 2006); or may have been enriched by higher risk patients due to features such as atypia or HGPIN on previous biopsies or other factors (Yanke *et al*, 2005; Benecchi *et al*, 2008).

The study is strengthened by the use of a well-characterised, prospective cohort that was a part of a rigorously conducted clinical trial. The use of decision analytical techniques and sensitivity analysis demonstrate the utility in clinical decision making across different threshold probabilities and cancer detection rates. An additional advantage of using a panel of four kallikrein markers is that it does not require additional procedures, such as urine collection or prostatic massage, and can be performed by laboratories using an aliquot from the same blood sample used to run the initial PSA. The model can also be incorporated into laboratory reports, which can then report the risk of prostate cancer for the patient along with the measure of each kallikrein.

## CONCLUSIONS

A statistical model based on a panel of four kallikreins has been previously shown to predict the outcome of prostate biopsy in previously unscreened men (Vickers *et al*, 2008, 2010c) and in men who had a PSA test but no previous biopsy (Vickers *et al*, 2010a, b). In this study, we show that the model is highly predictive of biopsy outcome. Use of the model to determine repeat biopsy in men with elevated PSA would dramatically reduce rebiopsy rates, while delaying the diagnosis of only a small number of cancers, almost all of which are low grade.

## ACKNOWLEDGEMENTS

We thank Gun-Britt Eriksson and Kerstin Håkansson for expert assistance with immunoassays. The work on this research was funded by a P50-CA92629 SPORE from the National Cancer

Institute (Pilot Project 7), Swedish Cancer Society project no. 0345, Swedish Research Council (Medicine) project no. 20095, European Union 6th Framework contract LSHC-CT-2004-503011 (P-Mark), Academy of Finland (Project 206690), Fundación Federico SA and by The Sidney Kimmel Center for Prostate and Urologic Cancers. The ERSPC Rotterdam study was funded by grants from the Dutch Cancer Society, the Netherlands Organisation for Health Research and Development, the prostate cancer research foundation (SWOP), 6th Framework Program of the EU: P-Mark and from

Beckman Coulter Hybritech. This work was supported in part by a grant from the AUA Foundation Research Scholars Program and the Astellas USA Foundation.

### Conflict of interest

Dr H Lilja holds patents for free PSA and hK2 assays, and, with Dr Kim Pettersson, is named as co-inventor on a patent application for intact/nicked PSA assays.

### REFERENCES

- Benecci L, Pieri AM, Melissari M, Potenzoni M, Pastizzaro CD (2008) A novel nomogram to predict the probability of prostate cancer on repeat biopsy. *J Urol* **180**(1): 146–149
- Catalona WJ, Beiser JA, Smith DS (1997) Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. *J Urol* **158**(6): 2162–2167
- Chun FK, Briganti A, Graefen M, Porter C, Montorsi F, Haese A, Scattoni V, Borden L, Steuber T, Salonia A, Schlomm T, Latchemsetty K, Walz J, Kim J, Eichelberg C, Currlin E, Ahyai SA, Erbersdobler A, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz PI (2007) Development and external validation of an extended repeat biopsy nomogram. *J Urol* **177**(2): 510–515
- Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M (2000) Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. *J Urol* **163**(4): 1144–1148; discussion 1148–9
- Durkan GC, Greene DR (1999) Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? *BJU Int* **83**(1): 34–38
- Fleshner NE, O'Sullivan M, Fair WR (1997) Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. *J Urol* **158**(2): 505–508; discussion 508–9
- Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. *Eur Urol* **54**(5): 1081–1088
- Keetch DW, Catalona WJ, Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. *J Urol* **151**(6): 1571–1574
- Kranse R, Roobol M, Schroder FH (2008) A graphical device to represent the outcomes of a logistic regression analysis. *Prostate* **68**(15): 1674–1680
- Lane BR, Zippe CD, Abouassaly R, Schoenfeld L, Magi-Galluzzi C, Jones JS (2008) Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. *J Urol* **179**(5): 1746–1750; discussion 1750
- Letran JL, Meyer GE, Loberiza FR, Brawer MK (1998) The effect of prostate volume on the yield of needle biopsy. *J Urol* **160**(5): 1718–1721
- Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW (2003) A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. *J Urol* **170**(4 Pt 1): 1184–1188; discussion 1188
- Lujan M, Paez A, Santonja C, Pascual T, Fernandez I, Berenguer A (2004) Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions. *Prostate Cancer Prostatic Dis* **7**(3): 238–242
- Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. *Urology* **69**(3): 532–535
- O'Dowd GJ, Miller MC, Orozco R, Veltri RW (2000) Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. *Urology* **55**(4): 553–559
- Park SJ, Miyake H, Hara I, Eto H (2003) Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. *Int J Urol* **10**(2): 68–71
- Radwan MH, Yan Y, Luly JR, Figenshau RS, Brandes SB, Bhayani SB, Bullock AD, Liefu Y, Andriole GL, Kibel AS (2007) Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. *Urology* **69**(6): 1121–1127
- Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schroder FH (1998) Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. *J Urol* **160**(6 Pt 1): 2121–2125
- Rochester MA, Pashayan N, Matthews F, Doble A, McLoughlin J (2009) Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. *BMC Urol* **9**: 7
- Roehrborn CG, Pickens GJ, Sanders JS (1996) Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. *Urology* **47**(3): 347–352
- Roobol MJ, Kirkels WJ, Schroder FH (2003) Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). *BJU Int* **92**(Suppl 2): 48–54
- Roobol MJ, Schroder FH, Kranse R (2006) A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55–75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). *Prostate* **66**(6): 604–612
- Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009a) Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* **360**(13): 1320–1328
- Schroder FH, van den Bergh RC, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, Roobol MJ (2009b) Eleven-Year Outcome of Patients with Prostate Cancers Diagnosed During Screening After Initial Negative Sextant Biopsies. *Eur Urol* **57**(2): 256–266
- Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. *Cancer* **113**(11): 3075–3099
- Stewart CS, Leibovich BC, Weaver AL, Lieber MM (2001) Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. *J Urol* **166**(1): 86–91; discussion 91–2
- Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman Jr CA (2006) Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* **98**(8): 529–534
- Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman Jr CA (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. *JAMA* **294**(1): 66–70
- Ulmert D, Cronin AM, Bjork T, O'Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, Vickers AJ, Lilja H (2008) Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. *BMC Med* **6**: 6
- Vaisanen V, Peltola MT, Lilja H, Nurmi M, Pettersson K (2006) Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')<sub>2</sub> fragments. *Anal Chem* **78**(22): 7809–7815
- Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H (2008) A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. *BMC Med* **6**: 19
- Vickers AJ, Cronin AM, Aus G, Pihl C, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H (2010a) Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. *Cancer* **116**(11): 2612–2620

- Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schroder FH, Lilja H (2010b) A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Prostate Cancer Screening, Rotterdam. *Clin Cancer Res* 16(12): 3232–3239
- Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schroder FH, Lilja H (2010c) Reducing unnecessary biopsy during prostate cancer screening using a four kallikrein panel: an independent replication. *J Clin Oncol* 28(15): 2493–2498
- Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI (2006) High incidence of prostate cancer detected

by saturation biopsy after previous negative biopsy series. *Eur Urol* 50(3): 498–505

Yanke BV, Gonen M, Scardino PT, Kattan MW (2005) Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. *J Urol* 173(2): 421–424



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>